Blonder Tongue Laboratories, Inc. (BDRLQ) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Blonder Tongue Laboratories, Inc. $0.00, price $0.00, upside +0.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Blonder Tongue Laboratories, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0001 – $2.22 · the $0.0002 price screens below the $0.0002 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.
Follow Blonder Tongue Laboratories in your weekly email
Every Wednesday you see whether Blonder Tongue Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers NXG modular IP video systems, CV transcoders, CV encoders, Aircaster off-air series, and the DRAKE series.
Show more
Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers NXG modular IP video systems, CV transcoders, CV encoders, Aircaster off-air series, and the DRAKE series. The company also provides video encoding and transcoding, analog modulators, receivers and modulators, data over cable service interface specification-cable modem termination systems, fiber optics, broadband amplifiers, test and measurement products, passives, and accessories. In addition, it provides end-of-life CableCARD solutions, secure reliable transport solutions, and local content solutions for hospitality networks. Blonder Tongue Laboratories, Inc. was founded in 1950 and is based in Old Bridge, New Jersey.
Stock analysis
Blonder Tongue Laboratories, Inc. (BDRLQ) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0002 per share, and 2 of the 8 models we run sit above the $0.0002 price.
Bear case: the DCF Models group reads lowest at $0.0002, and 6 of the 8 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Technology sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Blonder Tongue Laboratories, Inc. reported revenue of $11.2M in FY2024 versus $16.4M in FY2020, a compound −9.1%/yr. Reported net income was −$1.2M in FY2024.
Key figures
Market cap $5.8K · EPS (TTM) $−0.0900 · Net margin −11.2% · Return on equity −134% · Return on assets (EBIT) −24.3% · Operating margin 6.2% · Revenue (TTM) $18.1M · Revenue growth (YoY) +32.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 99% below its 52-week high and 100% above its 52-week low.
For context, the median of 10 Technology peers we cover trades at −62% fair-value upside, at 0%, BDRLQ screens cheaper than that median.
Fair Value models
Bear $0.0002Fair Value $0.0002Bull $0.0002
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.15/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.5% (2019) → −6.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Compare Blonder Tongue Laboratories, Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Communication Equipment · 295 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−9.9% · Bottom 25%
Net margin (TTM)−16.1% · Bottom 25%
Operating margin (TTM)6.2% · Above median
Growth and dividend
Revenue growth32.2% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Communication Equipment median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 0
FUTURE (revenue growth)100· sector 40
PAST (return on equity)0· sector 17
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 24
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Blonder Tongue Laboratories, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/BDRLQ
Frequently asked questions
Is Blonder Tongue Laboratories, Inc. (BDRLQ) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0002 versus the last price from Sep 25, 2026 of $0.0002, about +0% upside (fairly valued).
What is the fair value of BDRLQ?
Our model-based fair value for Blonder Tongue Laboratories, Inc. is $0.0002 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0002.
What is the quality score of BDRLQ?
Blonder Tongue Laboratories, Inc. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Blonder Tongue Laboratories, Inc. (BDRLQ)?
Our model-based price target is the fair value of $0.0002 (as of Sep 27, 2026) from 8 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Blonder Tongue Laboratories, Inc. stock forecast for 2026?
Our models put fair value at $0.0002, about +0% upside versus the last price from Sep 25, 2026 of $0.0002 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Blonder Tongue Laboratories, Inc. (BDRLQ)?
Blonder Tongue Laboratories, Inc. reported trailing-twelve-month revenue of about $18.1M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Blonder Tongue Laboratories, Inc. (BDRLQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Blonder Tongue Laboratories, Inc. it is $0.0002 per share (as of Sep 27, 2026), against a price of $0.0002. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Blonder Tongue Laboratories, Inc. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BDRLQ trades below its calculated fair value: price $0.0002, fair value $0.0002, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BDRLQ?
No. The price is what the market pays today ($0.0002); the fair value is what the company's own numbers justify ($0.0002). For Blonder Tongue Laboratories, Inc. the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Blonder Tongue Laboratories, Inc. worth?
The market values Blonder Tongue Laboratories, Inc. at about $5.8K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0002; our models calculate a fair value of $0.0002 per share.
How solid is the balance sheet of Blonder Tongue Laboratories, Inc. (BDRLQ)?
Balance-sheet figures for Blonder Tongue Laboratories, Inc. (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is BDRLQ from its 52-week high?
Blonder Tongue Laboratories, Inc. trades at $0.0002, about 99% below its 52-week high of $0.0348 and 100% above the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0002 is for.
Which stocks are comparable to Blonder Tongue Laboratories, Inc.?
From the same area (Technology) we also value Cisco Systems, Inc, Foxconn Industrial Internet Co, Zhongji Innolight Co, Eoptolink Technology Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Blonder Tongue Laboratories, Inc. stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0002, calculated fair value $0.0002 (+0%), Quality Score 53/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BDRLQ calculated?
We run Blonder Tongue Laboratories, Inc. through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0002, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Blonder Tongue Laboratories, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Blonder Tongue Laboratories, Inc. (BDRLQ)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0002. Our model-based fair value is $0.0002, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Blonder Tongue Laboratories, Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Blonder Tongue Laboratories, Inc.
How large is the market capitalisation of Blonder Tongue Laboratories, Inc. (BDRLQ)?
The market capitalisation of Blonder Tongue Laboratories, Inc. is $5.8K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Blonder Tongue Laboratories, Inc. (BDRLQ)?
Earnings per share at Blonder Tongue Laboratories, Inc. are $−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Blonder Tongue Laboratories, Inc. (BDRLQ)?
The net margin of Blonder Tongue Laboratories, Inc. is −11.2% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Blonder Tongue Laboratories, Inc. (BDRLQ)?
The return on equity (ROE) of Blonder Tongue Laboratories, Inc. is −134% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Blonder Tongue Laboratories, Inc. (BDRLQ)?
On an EBIT basis the return on assets of Blonder Tongue Laboratories, Inc. is −24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Blonder Tongue Laboratories, Inc. (BDRLQ)?
The operating margin of Blonder Tongue Laboratories, Inc. is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Blonder Tongue Laboratories, Inc. (BDRLQ)?
Revenue at Blonder Tongue Laboratories, Inc. is growing +32.2% versus a year earlier (3y avg −10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Blonder Tongue Laboratories, Inc. (BDRLQ) generate?
The free cash flow of Blonder Tongue Laboratories, Inc. is $1.0M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Blonder Tongue Laboratories, Inc. (BDRLQ) carry?
The net debt of Blonder Tongue Laboratories, Inc. is $8.1M (fiscal year 2024, ≈ 7.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Blonder Tongue Laboratories, Inc. in the live analysis
One click puts Blonder Tongue Laboratories, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026